Breakthrough Clinical Trial Results in New Standard of Care for Esophageal and Gastroesophageal Junction Cancer
April 01, 2021
April 01, 2021
DALLAS, Texas, April 1 (TNSJou) -- Baylor Scott and White Health issued the following news release on March 31, 2021:
The results of a study published today in The New England Journal of Medicine found that the immunotherapy drug nivolumab (Opdivo(R)), if used following neoadjuvant chemoradiation therapy and surgical resection for early-stage esophageal or gastroesophageal junction cancers, can significantly prolong disease-free survival and reduce risk of disease recurrence.
. . .
The results of a study published today in The New England Journal of Medicine found that the immunotherapy drug nivolumab (Opdivo(R)), if used following neoadjuvant chemoradiation therapy and surgical resection for early-stage esophageal or gastroesophageal junction cancers, can significantly prolong disease-free survival and reduce risk of disease recurrence.
. . .